<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895215</url>
  </required_header>
  <id_info>
    <org_study_id>AXL-2004-002</org_study_id>
    <nct_id>NCT04895215</nct_id>
  </id_info>
  <brief_title>AB-2004 in Treatment of Adolescents With Irritability Associated With Autism Spectrum Disorder (ASD)</brief_title>
  <official_title>A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13 to 17 Year-old Autism Spectrum Disorder Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axial Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axial Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the potential benefits, safety, and tolerability of&#xD;
      AB-2004 in adolescent participants, aged 13 to 17, with irritability associated with autism&#xD;
      spectrum disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind, Randomized, Placebo Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004 High Dose</measure>
    <time_frame>From baseline to Week 8 visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004 Low Dose</measure>
    <time_frame>From baseline to Week 8 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in the Clinical Global Impression-Severity (CGI-S) from Baseline to Week 8 for AB-2004 High Dose and AB-2004 Low Dose</measure>
    <time_frame>From baseline to Week 8 visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who reported treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline to Week 8 visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Autism Spectrum Disorder (ASD)</condition>
  <arm_group>
    <arm_group_label>AB-2004 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AB-2004 Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB-2004</intervention_name>
    <description>Taken 3 times daily with food</description>
    <arm_group_label>AB-2004 High dose</arm_group_label>
    <arm_group_label>AB-2004 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take 3 times daily with food</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Clinically diagnosed, documented ASD (Diagnostic and Statistical Manual of Mental&#xD;
             Disorders [DSM-5] criteria)&#xD;
&#xD;
          -  Aberrant Behavior Checklist - Irritability (ABC-I) score ≥18 at the screening visit&#xD;
&#xD;
          -  Clinical Global Impression - Severity (CGI-S) scale score ≥4 at the screening visit&#xD;
&#xD;
          -  Presence of gastrointestinal symptoms (diarrhea, constipation, abdominal pain,&#xD;
             bloating) at the screening visit&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Use of an oral, injected, or inhaled antibiotic within 30 days prior to screening.&#xD;
             Prophylactic oral antibiotic use of no more than 1 dose will be permitted&#xD;
&#xD;
          -  Current use of an oral controlled or extended-release medication&#xD;
&#xD;
          -  Have a comorbid major psychiatric condition (eg, schizophrenia or bipolar disorder) at&#xD;
             screening that in the opinion of the Investigator may interfere with the subject's&#xD;
             ability to complete study procedures/comply with study requirements&#xD;
&#xD;
          -  Current use of antipsychotics (eg, aripiprazole or risperidone)&#xD;
&#xD;
          -  Failure to respond to atypical antipsychotic drugs at therapeutic doses for 4 weeks or&#xD;
             longer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Team</last_name>
    <phone>+1 781-701-8484</phone>
    <email>clinicaltrialteam@axialtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southwestern Autism Research and Resource Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Crisler</last_name>
      <email>ACrisler@autismcenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joceline Serino</last_name>
      <email>jocelineserino@peds.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Davis-MIND Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erika Bickel</last_name>
      <email>esbickel@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felicia Widjaja</last_name>
      <email>felicia.widjaja@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cortica WestLake Village</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chester Camia</last_name>
      <email>ccamia@corticacare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University, Child Study Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aniela Bordofsky</last_name>
      <email>aniela.bordofsky@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Solutions</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Jandir</last_name>
      <email>sjandir@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad Littlejohn, MA, LMHC, CCRC</last_name>
      <email>blittlejohn@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Samson</last_name>
      <email>jsamson@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baber Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freeda Baber</last_name>
      <email>freeda@baberresearchgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LSU Health- Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Saunders</last_name>
      <email>stephanie.saunders@lsuhs.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital, Lurie Center</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Mullett</last_name>
      <email>jmullett@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catherine Masters</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Masters</last_name>
      <email>catherinem@neurobmg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Childress, MD</last_name>
      <email>drann87@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nathan S. Kline Institute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Breland</last_name>
      <phone>845-398-5525</phone>
      <email>melissa.breland@nki.rfmh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priya Selvarajah</last_name>
      <email>pselvarajah@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Orion Biesan</last_name>
      <email>orion.biesan@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University, Nisonger Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arielle Mulligan</last_name>
      <email>Arielle.Mulligan@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Goldsby</last_name>
      <email>sgoldsby@woodlandspsych.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carilion Medical Center</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryce Lewis</last_name>
      <email>brlewis@carilionclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Health Queensland Hospital</name>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Larkin</last_name>
      <email>chq_cctrnd@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Optimal Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Lim</last_name>
      <email>Nicole@optimalclinicaltrials.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

